Bayer Aktienges Ads (BAYRY) 144.4800 $BAYRY
Bayer to Shed MaterialScience Business, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:10PM CDT
Bayer (BAYRY) announced its intention to shed its MaterialScience business and focus fully on its HealthCare and CropScience segments.
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:15PM CDT
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.
Bayer to split off polymer division with IPO
AP - Thu Sep 18, 8:44AM CDT
BERLIN (AP) — German pharmaceuticals and chemicals company Bayer AG said Thursday it plans to spin off its polymer division with a separate stock listing.
Why Bayer (BAYRY) Stock Is Surging Today
at The Street - Thu Sep 18, 7:25AM CDT
Bayer (BAYRY) plans to list its less profitable plastics business on the stock market in a deal that could value the division at about $13 billion.
Animal Healthcare Market - Global Industry Analysis 2014 - 2019: Segment, Animal type and Regional Analysis
M2 - Tue Sep 16, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knrxpc/animal_healthcare) has announced the addition of the "Animal Healthcare Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019 Market" report to their offering. The global animal healthcare market is growing due to the increasing animal population of both types: companion and production. Companion animals are those which people tame or adopt for companionship, house/office guards and production animals are raised for meat and milk-related products. The new diseases in animals and their transfer to humans via their product consumption and companionship are also propelling the animal healthcare market globally. However, some challenges have emerged in the form of regulations against the excess use of antibiotics in production animals, and legislations and protest of animal activists and institutions against animal research. The animal healthcare market is very competitive with the top ten players accounting for about 75% of the market and every company focusing on research and development to produce better pharmaceutical and vaccine products for the existing diseases. The animal healthcare market is categorized under three broad segments, namely feed additives, pharmaceuticals and vaccines. Feed additives can be categorized as nutritional feed additives and medicinal feed additives. Nutritional feed additives comprise amino acids, minerals and vitamins and are used for production animals for their optimal growth. Medicinal feed additives comprise hormones, enzymes, immune-modulators, probiotics and prebiotics and feed acidifiers which target specific diseases in production and companion animals. Pharmaceutical products mainly include endoparasiticides, ectoparasiticides, endectocides, antibiotics, anti-inflammatories and medicines for reproductive problems. Vaccines make animals disease-immune for a particular disease. In biological terms, vaccination against a particular pathogen aims to mimic the development of naturally acquired immunity by inoculation of non-pathogenic but immunogenic components of that pathogen.omponents of that pathogen. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Animal Healthcare Market - Industry Overview Chapter 4 Global Animal Healthcare Market: By Product Segment Chapter 5 Global Animal Healthcare Market: By Animal Type Chapter 6 Global Animal Healthcare Market: By Region Chapter 7 Competitive Landscape Chapter 8 Company Profiles - Bayer AG - Boehringer Ingelheim GmbH - Ceva Sant? Animale - Elanco Products Company - MERIAL Limited - Merck & Co., Inc. - Novartis Animal Health Inc. - Virbac SA - V?toquinol SA - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/kn...healthcare
United States Seeks Civil Contempt Against Bayer Corporation for Failure to Substantiate Promotional Claims for Phillips' Colon Health
M2 - Mon Sep 15, 7:48AM CDT
The Department of Justice announced today that it filed a motion to show cause why Bayer Corporation should not be held in civil contempt for violating a court order in the U.S. District Court for the District of New Jersey. The court order, entered in 2007 in United States v. Bayer Corporation , prohibits Bayer from making unsubstantiated claims for any dietary supplement it promotes or sells. The government alleges in today's motion that Bayer promotes one of its products, Phillips' Colon Health, using claims about the product's purported benefits without having evidence to substantiate those claims.
Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:30PM CDT
Sanofi's (SNY) subsidiary, Genzyme, announced positive interim data on its multiple sclerosis (MS) candidate, Lemtrada (alemtuzumab), from the second year of an extension study.
Latin America Home Healthcare (Diagnostics and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility Assist Devices and Medical Supplies) Market 2014-2020
M2 - Fri Sep 12, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63pfn7/latin_america) has announced the addition of the "Latin America Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The Latin America home healthcare market is estimated to be USD 9,796.8 million in 2013 and is expected to reach USD 17,550.0 million by 2020, growing at a CAGR of 8.7% from 2014 to 2020 Home healthcare represents use of medical devices and community based services to support patients suffering from chronic diseases. Currently, the home healthcare market is moving towards a precision-based model of personal care. Home-based medical devices and services play an important role in providing personal care to patients in managing variety of disease conditions such as diabetes, chronic obstructive pulmonary disease and blood pressure. Increasing patient population with chronic diseases such as diabetes, blood pressure, cardiovascular conditions and respiratory diseases globally (including Latin America) would drive the demand for home-based medical devices and services. These diseases require continuous monitoring, and thus involve high cost due to repeated visits to healthcare centers that inflate medical expenses. Thus, home healthcare devices and services are being rapidly adopted by consumers to measure parameters on a regular basis and to cut down medical costs. Latin America home healthcare market is mainly segmented into device types and services. Latin America home healthcare device segment is considered to be the largest segment and is estimated to grow at the highest CAGR during the forecast period from 2014 to 2020. This growth was mainly attributed to high acceptance of medical devices coupled with technological advancements (introduction of automated and portable devices) to fuel the growth of the home healthcare devices market in Latin America. The market of ventilators and CPAP devices segment is estimated to grow at the highest CAGR of 11.4% from 2014 to 2020. The mobility assist devices segment is further categorized into wheelchairs, cranes and crutches and other home mobility assist devices. Latin America home healthcare market, by services is segmented as rehabilitation services, intuition therapy services, telehealth and telemedicine services, respiratory therapy services and unskilled home healthcare services. The Latin American market of unskilled home healthcare services accounted for the largest market share i.e. more than 45% of total Latin American home healthcare services market in 2013. The telehealth and telemedicine services segment is estimated to grow at the highest growth rate from 2014 to 2020. The Latin American home healthcare market is segmented as follows: Latin American Home Healthcare Market, by Device Types - Diagnostics and Monitoring Home Devices - - Blood Glucose Monitors - - Blood Pressure Monitors - - Heart Rate Monitors - - Temperature Monitors - - Sleep Apnea Monitors - - Coagulation Monitors - - Pregnancy Test Kits - - Pulse Oximeters - - Pedometers - Therapeutics Home Healthcare Devices - - Insulin Delivery Devices - - Nebulizers - - Ventilator and CPAP Devices - - IV Equipments - - Dialysis Equipment - Home Mobility Assist Devices - - Wheelchairs - - Cranes and Crutches - - Other Home Mobility Assist Devices - Medical Supplies Latin American Home Healthcare Market, by Services - Rehabilitation Services - Telehealth and Telemedicine Services - Infusion Therapy Services - Respiratory Therapy Services - Unskilled Home Healthcare Services Companies Mentioned - 3M Healthcare - Abbott Laboratories - Bayer AG - Cardinal Health - F. Hoffmann-La Roche Ltd. - GE Healthcare - Gentiva Health Services, Inc. - Invacare Corporation - Johnson & Johnson Services, Inc. - Medtronic, Inc. - Omron Healthcare, Inc. - Philips Healthcare - Praxair Technologies, Inc. - ResMed, Inc. - Teleflex Incorporated - The Linde Group For more information visit http://www.researchandmarkets.com/research/63...in_america
Global Malignant Mesothelioma Therapeutics Pipeline Review 2014 - 11 Companies & 25 Companies
M2 - Fri Sep 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qjk7h/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals Inc. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - BNC-105 - FPI-01 - YS-110 - BIW-8962 - Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - ONCOS-102 - Drug For Mesothelioma - Oshadi D Oshadi R - AEOL-10150 - anetumab ravtansine - LY-3023414 - Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - VS-4718 - VS-5584 - BERTA - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Ad5-SGE-REIC/Dkk3 Gene Therapy - pemetrexed disodium - Vaccine For Cancer - YP-223 - YYP-218 - YP-3 - DP-3975 - Tb-535C - SentoClone For more information visit http://www.researchandmarkets.com/research/8qjk7h/malignant
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles
M2 - Fri Sep 12, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl7j38/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Novartis AG - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Semafore Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - AB Science Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - motesanib diphosphate - olaratumab - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib besylate - luminespib - (dabrafenib trametinib) - pazopanib hydrochloride - binimetinib - TH-302 - SF-1126 - CS-2164 - Vaccine Targeting NY-ESO-1 for Oncology - buparlisib hydrochloride - X-82 - quizartinib - DCC-2618 - Small Molecules Targeting c-Kit for Gastrointestinal Stromal Tumor For more information visit http://www.researchandmarkets.com/research/hl...intestinal
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:25PM CDT
Bayer (BAYRY) announced positive results from long-term extension studies on Adempas.
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.
Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:45PM CDT
Bayer submitted an MAA for Eylea in Japan for the treatment of patients suffering from macular edema secondary to BRVO.
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Market for Polycarbonate - Forecast, Trends & Opportunities 2014-2020
M2 - Mon Sep 08, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ltdpp/global_market_for) has announced the addition of the "Global Market for Polycarbonate - Forecast, Trends & Opportunities 2014-2020" report to their offering. The global demand for polycarbonate is likely to cross 6,000,000 tons by 2020, while the production of polycarbonates is expected to reach nearly 5,000,000 tons by 2020. Polycarbonates are a particular group of thermoplastic polymers that are generally known by the trademarked names like Makrolon, Makroclear, arcoPlus, Lexan, etc. Polycarbonates have a unique property that they can be easily molded and thermoformed and they are easy to work with as well. These properties have made polycarbonates quite attractive an option for many industries ranging from automobiles, electronics and electricals, opticals, amongst others. Optical media remains one of the principal applications of polycarbonates. The global market for polycarbonates is expected to show good growth in the coming years. The global polycarbonate market was dominated by the Asia Pacific region. North America and Europe followed next as well. The Asia Pacific region accounted for more than 60% of the demand for polycarbonates in the world. In the Asia Pacific region, China accounted for nearly 60% of the polycarbonate demand and was also the largest polycarbonate consumer globally. Investors have now shifted focus on building up the polycarbonate capacity in the Middle East & Africa region. The MEA region is now expanding as a polycarbonate manufacturing hub primarily due to the easy availability of low cost feedstock in the region. By 2020, the MEA region is expected to establish itself as a major exporter of polycarbonate. Key Topics Covered: 1. Executive Summary 2. Introduction To Polycarbonates 3. Global Market For Polycarbonate 4. Global Polycarbonate Market: Analysis By Regions 5. Global Polycarbonate Market: Analysis Of Key Markets 6. Impacts On The Global Polycarbonate Market 7. Global Polycarbonate Market: Competitive Landscape & Major Players - Asahi Kasei Corporation - Bayer AG - Chi Mei Corporation - Formosa Plastics Group - Honam Petrochemical Corporation (now Lotte Chemical Corporation) - Idemitsu Kosan Co., Ltd. - LG Chem Ltd - Mitsubishi Chemical Holdings Corporation - Mitsubishi Engineering-Plastics Corporation - Mitsubishi Gas Chemical Co - Samsung Petrochemical Co., Ltd. - Samyang Corporation - Saudi Basic Industries Corporation - Shanghai Chlor-Alkali Chemical Co., Ltd - Teijin Limited - The Dow Chemical Company - Unigel Plasticos SA For more information visit http://www.researchandmarkets.com/research/5l...market_for
The Surprising Over-the-Counter Pain Reliever Consumers Are Least Loyal To
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 06, 8:23AM CDT
Source: Anthony Easton via Flickr . If you're anything like me, walking down the first-aid aisle in the grocery store or drugstore creates a deer in the headlights look nearly every time. The amount of over-the-counter therapeutics that consumers...
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:12PM CDT
The Dow had a lacklustre week after weakness in energy shares and a series of other concerns dampened investor sentiment.
Bayer Discloses Encouraging Data on Anticoagulant Xarelto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 4:10PM CDT
Bayer (BAYRY) announced encouraging results from the X-VeRT study on Xarelto.
Bayer/Johnson & Johnson to Expand Xarelto Label Further - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:30PM CDT
Bayer (BAYRY) and Johnson & Johnson (JNJ) announced that they will be evaluating Xarelto in three new indications.
Bayer to Shed MaterialScience Business, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:10PM CDT
Bayer (BAYRY) announced its intention to shed its MaterialScience business and focus fully on its HealthCare and CropScience segments.
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:15PM CDT
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.
Bayer to split off polymer division with IPO
AP - Thu Sep 18, 8:44AM CDT
BERLIN (AP) — German pharmaceuticals and chemicals company Bayer AG said Thursday it plans to spin off its polymer division with a separate stock listing.
Why Bayer (BAYRY) Stock Is Surging Today
at The Street - Thu Sep 18, 7:25AM CDT
Bayer (BAYRY) plans to list its less profitable plastics business on the stock market in a deal that could value the division at about $13 billion.
Animal Healthcare Market - Global Industry Analysis 2014 - 2019: Segment, Animal type and Regional Analysis
M2 - Tue Sep 16, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knrxpc/animal_healthcare) has announced the addition of the "Animal Healthcare Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019 Market" report to their offering. The global animal healthcare market is growing due to the increasing animal population of both types: companion and production. Companion animals are those which people tame or adopt for companionship, house/office guards and production animals are raised for meat and milk-related products. The new diseases in animals and their transfer to humans via their product consumption and companionship are also propelling the animal healthcare market globally. However, some challenges have emerged in the form of regulations against the excess use of antibiotics in production animals, and legislations and protest of animal activists and institutions against animal research. The animal healthcare market is very competitive with the top ten players accounting for about 75% of the market and every company focusing on research and development to produce better pharmaceutical and vaccine products for the existing diseases. The animal healthcare market is categorized under three broad segments, namely feed additives, pharmaceuticals and vaccines. Feed additives can be categorized as nutritional feed additives and medicinal feed additives. Nutritional feed additives comprise amino acids, minerals and vitamins and are used for production animals for their optimal growth. Medicinal feed additives comprise hormones, enzymes, immune-modulators, probiotics and prebiotics and feed acidifiers which target specific diseases in production and companion animals. Pharmaceutical products mainly include endoparasiticides, ectoparasiticides, endectocides, antibiotics, anti-inflammatories and medicines for reproductive problems. Vaccines make animals disease-immune for a particular disease. In biological terms, vaccination against a particular pathogen aims to mimic the development of naturally acquired immunity by inoculation of non-pathogenic but immunogenic components of that pathogen.omponents of that pathogen. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Animal Healthcare Market - Industry Overview Chapter 4 Global Animal Healthcare Market: By Product Segment Chapter 5 Global Animal Healthcare Market: By Animal Type Chapter 6 Global Animal Healthcare Market: By Region Chapter 7 Competitive Landscape Chapter 8 Company Profiles - Bayer AG - Boehringer Ingelheim GmbH - Ceva Sant? Animale - Elanco Products Company - MERIAL Limited - Merck & Co., Inc. - Novartis Animal Health Inc. - Virbac SA - V?toquinol SA - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/kn...healthcare
United States Seeks Civil Contempt Against Bayer Corporation for Failure to Substantiate Promotional Claims for Phillips' Colon Health
M2 - Mon Sep 15, 7:48AM CDT
The Department of Justice announced today that it filed a motion to show cause why Bayer Corporation should not be held in civil contempt for violating a court order in the U.S. District Court for the District of New Jersey. The court order, entered in 2007 in United States v. Bayer Corporation , prohibits Bayer from making unsubstantiated claims for any dietary supplement it promotes or sells. The government alleges in today's motion that Bayer promotes one of its products, Phillips' Colon Health, using claims about the product's purported benefits without having evidence to substantiate those claims.
Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:30PM CDT
Sanofi's (SNY) subsidiary, Genzyme, announced positive interim data on its multiple sclerosis (MS) candidate, Lemtrada (alemtuzumab), from the second year of an extension study.
Latin America Home Healthcare (Diagnostics and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility Assist Devices and Medical Supplies) Market 2014-2020
M2 - Fri Sep 12, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63pfn7/latin_america) has announced the addition of the "Latin America Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The Latin America home healthcare market is estimated to be USD 9,796.8 million in 2013 and is expected to reach USD 17,550.0 million by 2020, growing at a CAGR of 8.7% from 2014 to 2020 Home healthcare represents use of medical devices and community based services to support patients suffering from chronic diseases. Currently, the home healthcare market is moving towards a precision-based model of personal care. Home-based medical devices and services play an important role in providing personal care to patients in managing variety of disease conditions such as diabetes, chronic obstructive pulmonary disease and blood pressure. Increasing patient population with chronic diseases such as diabetes, blood pressure, cardiovascular conditions and respiratory diseases globally (including Latin America) would drive the demand for home-based medical devices and services. These diseases require continuous monitoring, and thus involve high cost due to repeated visits to healthcare centers that inflate medical expenses. Thus, home healthcare devices and services are being rapidly adopted by consumers to measure parameters on a regular basis and to cut down medical costs. Latin America home healthcare market is mainly segmented into device types and services. Latin America home healthcare device segment is considered to be the largest segment and is estimated to grow at the highest CAGR during the forecast period from 2014 to 2020. This growth was mainly attributed to high acceptance of medical devices coupled with technological advancements (introduction of automated and portable devices) to fuel the growth of the home healthcare devices market in Latin America. The market of ventilators and CPAP devices segment is estimated to grow at the highest CAGR of 11.4% from 2014 to 2020. The mobility assist devices segment is further categorized into wheelchairs, cranes and crutches and other home mobility assist devices. Latin America home healthcare market, by services is segmented as rehabilitation services, intuition therapy services, telehealth and telemedicine services, respiratory therapy services and unskilled home healthcare services. The Latin American market of unskilled home healthcare services accounted for the largest market share i.e. more than 45% of total Latin American home healthcare services market in 2013. The telehealth and telemedicine services segment is estimated to grow at the highest growth rate from 2014 to 2020. The Latin American home healthcare market is segmented as follows: Latin American Home Healthcare Market, by Device Types - Diagnostics and Monitoring Home Devices - - Blood Glucose Monitors - - Blood Pressure Monitors - - Heart Rate Monitors - - Temperature Monitors - - Sleep Apnea Monitors - - Coagulation Monitors - - Pregnancy Test Kits - - Pulse Oximeters - - Pedometers - Therapeutics Home Healthcare Devices - - Insulin Delivery Devices - - Nebulizers - - Ventilator and CPAP Devices - - IV Equipments - - Dialysis Equipment - Home Mobility Assist Devices - - Wheelchairs - - Cranes and Crutches - - Other Home Mobility Assist Devices - Medical Supplies Latin American Home Healthcare Market, by Services - Rehabilitation Services - Telehealth and Telemedicine Services - Infusion Therapy Services - Respiratory Therapy Services - Unskilled Home Healthcare Services Companies Mentioned - 3M Healthcare - Abbott Laboratories - Bayer AG - Cardinal Health - F. Hoffmann-La Roche Ltd. - GE Healthcare - Gentiva Health Services, Inc. - Invacare Corporation - Johnson & Johnson Services, Inc. - Medtronic, Inc. - Omron Healthcare, Inc. - Philips Healthcare - Praxair Technologies, Inc. - ResMed, Inc. - Teleflex Incorporated - The Linde Group For more information visit http://www.researchandmarkets.com/research/63...in_america
Global Malignant Mesothelioma Therapeutics Pipeline Review 2014 - 11 Companies & 25 Companies
M2 - Fri Sep 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qjk7h/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals Inc. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - BNC-105 - FPI-01 - YS-110 - BIW-8962 - Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - ONCOS-102 - Drug For Mesothelioma - Oshadi D Oshadi R - AEOL-10150 - anetumab ravtansine - LY-3023414 - Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - VS-4718 - VS-5584 - BERTA - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Ad5-SGE-REIC/Dkk3 Gene Therapy - pemetrexed disodium - Vaccine For Cancer - YP-223 - YYP-218 - YP-3 - DP-3975 - Tb-535C - SentoClone For more information visit http://www.researchandmarkets.com/research/8qjk7h/malignant
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles
M2 - Fri Sep 12, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl7j38/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Novartis AG - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Semafore Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - AB Science Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - motesanib diphosphate - olaratumab - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib besylate - luminespib - (dabrafenib trametinib) - pazopanib hydrochloride - binimetinib - TH-302 - SF-1126 - CS-2164 - Vaccine Targeting NY-ESO-1 for Oncology - buparlisib hydrochloride - X-82 - quizartinib - DCC-2618 - Small Molecules Targeting c-Kit for Gastrointestinal Stromal Tumor For more information visit http://www.researchandmarkets.com/research/hl...intestinal
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:25PM CDT
Bayer (BAYRY) announced positive results from long-term extension studies on Adempas.
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.
Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:45PM CDT
Bayer submitted an MAA for Eylea in Japan for the treatment of patients suffering from macular edema secondary to BRVO.
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Market for Polycarbonate - Forecast, Trends & Opportunities 2014-2020
M2 - Mon Sep 08, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ltdpp/global_market_for) has announced the addition of the "Global Market for Polycarbonate - Forecast, Trends & Opportunities 2014-2020" report to their offering. The global demand for polycarbonate is likely to cross 6,000,000 tons by 2020, while the production of polycarbonates is expected to reach nearly 5,000,000 tons by 2020. Polycarbonates are a particular group of thermoplastic polymers that are generally known by the trademarked names like Makrolon, Makroclear, arcoPlus, Lexan, etc. Polycarbonates have a unique property that they can be easily molded and thermoformed and they are easy to work with as well. These properties have made polycarbonates quite attractive an option for many industries ranging from automobiles, electronics and electricals, opticals, amongst others. Optical media remains one of the principal applications of polycarbonates. The global market for polycarbonates is expected to show good growth in the coming years. The global polycarbonate market was dominated by the Asia Pacific region. North America and Europe followed next as well. The Asia Pacific region accounted for more than 60% of the demand for polycarbonates in the world. In the Asia Pacific region, China accounted for nearly 60% of the polycarbonate demand and was also the largest polycarbonate consumer globally. Investors have now shifted focus on building up the polycarbonate capacity in the Middle East & Africa region. The MEA region is now expanding as a polycarbonate manufacturing hub primarily due to the easy availability of low cost feedstock in the region. By 2020, the MEA region is expected to establish itself as a major exporter of polycarbonate. Key Topics Covered: 1. Executive Summary 2. Introduction To Polycarbonates 3. Global Market For Polycarbonate 4. Global Polycarbonate Market: Analysis By Regions 5. Global Polycarbonate Market: Analysis Of Key Markets 6. Impacts On The Global Polycarbonate Market 7. Global Polycarbonate Market: Competitive Landscape & Major Players - Asahi Kasei Corporation - Bayer AG - Chi Mei Corporation - Formosa Plastics Group - Honam Petrochemical Corporation (now Lotte Chemical Corporation) - Idemitsu Kosan Co., Ltd. - LG Chem Ltd - Mitsubishi Chemical Holdings Corporation - Mitsubishi Engineering-Plastics Corporation - Mitsubishi Gas Chemical Co - Samsung Petrochemical Co., Ltd. - Samyang Corporation - Saudi Basic Industries Corporation - Shanghai Chlor-Alkali Chemical Co., Ltd - Teijin Limited - The Dow Chemical Company - Unigel Plasticos SA For more information visit http://www.researchandmarkets.com/research/5l...market_for
The Surprising Over-the-Counter Pain Reliever Consumers Are Least Loyal To
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 06, 8:23AM CDT
Source: Anthony Easton via Flickr . If you're anything like me, walking down the first-aid aisle in the grocery store or drugstore creates a deer in the headlights look nearly every time. The amount of over-the-counter therapeutics that consumers...
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:12PM CDT
The Dow had a lacklustre week after weakness in energy shares and a series of other concerns dampened investor sentiment.
Bayer Discloses Encouraging Data on Anticoagulant Xarelto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 4:10PM CDT
Bayer (BAYRY) announced encouraging results from the X-VeRT study on Xarelto.
Bayer/Johnson & Johnson to Expand Xarelto Label Further - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:30PM CDT
Bayer (BAYRY) and Johnson & Johnson (JNJ) announced that they will be evaluating Xarelto in three new indications.
